The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial
Open accessAbstract
Long-term adherence and persistence with any therapy are very poor ( approximately 50%). Adherence to therapy is defined as the percentage of prescribed medication taken, and persistence is defined as continuing to take prescribed medication. We examined whether monitoring by nursing staff could enhance adherence and persistence with antiresorptive therapy and whether presenting information on response to therapy provided additional benefit. In addition we evaluated the impact of monitoring on treatment efficacy. Seventy-five postmenopausal women with osteopenia were randomized to 1) no monitoring, 2) nurse-monitoring, or 3) marker-monitoring. All subjects were prescribed raloxifene. At 12, 24, and 36 wk, the nursing staff reviewed subjects in the monitored (nurse-monitoring or marker-monitoring) groups using a predefined protocol. The marker-monitored group were also presented a graph of response to therapy using percentage change in urinary N-telopeptide of type I collagen (uNTX), a bone resorption marker, at each visit. Biological response to therapy at 1 yr was determined using the percent change in bone mineral density (BMD) and uNTX. Treatment adherence and persistence were assessed using electronic monitoring devices. Survival analysis showed that the monitored group increased cumulative adherence to therapy by 57% compared with no monitoring (P = 0.04). There was a trend for the monitored group to persist with therapy for 25% longer compared with no monitoring (P = 0.07). Marker measurements did not improve adherence or persistence to therapy compared with nurse-monitoring alone. Adherence at 1 yr was correlated with percent change in hip (BMD) (r = 0.28; P = 0.01) and percent change in uNTX (r = -0.36; P = 0.002). In conclusion, monitoring of patients increased adherence to therapy by 57% at 1 yr. Increased adherence to therapy increased the effectiveness of raloxifene therapy determined using surrogate end points.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A.-C., Shah, A. S., Huster, W. J., Draper, M., & Christiansen, C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712043372301 · Cited by 1,637
Interventions to Enhance Patient Adherence to Medication Prescriptions: Scientific Review
McDonald, H. P., Garg, A. X., & Haynes, R. B. (2002) · JAMA · doi:10.1001/jama.288.22.2868 · Cited by 1,176
Interventions for helping patients to follow prescriptions for medications
Haynes, R., McDonald, H., Garg, A., & Montague, P. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011 · Cited by 911
Cummings, S. R. (1999) · Medical Entomology and Zoology · Cited by 797
Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752
The Use of Biochemical Markers of Bone Turnover in Osteoporosis
Delmas, P. D., Eastell, R., Garnero, P., Seibel, M. J., & Stepan, J. (2000) · Osteoporosis International · doi:10.1007/s001980070002 · Cited by 722
Self-citationRelationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
Eastell, R., Barton, I., Hannon, R., Chines, A., Garnero, P., & Delmas, P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1051 · Cited by 588
Self-citationAntifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density
Wasnich, R. D. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.231 · Cited by 417
Hannon, R., Blumsohn, A., Naylor, K., & Eastell, R. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.7.1124 · Cited by 257
Self-citationRiggs, B. L., & Melton, L. J. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.1.11 · Cited by 248
Monitoring Skeletal Changes by Radiological Techniques
Glüer, C.-C. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.11.1952 · Cited by 244
Time to stop counting the tablets?
Pullar, T., Kumar, S., Tindall, H., & Feely, M. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.121 · Cited by 237
Bjarnason, N. H., Sarkar, S., Duong, T., Mitlak, B., Delmas, P. D., & Christiansen, C. (2001) · Osteoporosis International · doi:10.1007/s001980170020 · Cited by 230
The natural history of medication compliance in a drug trial: Limitations of pill counts
Rudd, P., Byyny, R. L., Zachary, V., LoVerde, M. E., Titus, C., Mitchell, W. D., & Marshall, G. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.122 · Cited by 205
Role of Patient Compliance in Clinical Pharmacokinetics: A Review of Recent Research
Urquhart, J. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199427030-00004 · Cited by 196
Adverse events reported by postmenopausal women in controlled trials with raloxifene
Davies, G. (1999) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(98)00476-1 · Cited by 195
Results of Bone Densitometry Affect Women's Decisions about Taking Measures To Prevent Fractures
Rubin, S. M., & Cummings, S. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-12-990 · Cited by 181
Impact of the Hawthorne Effect in a Longitudinal Clinical Study
De Amici, D., Klersy, C., Ramajoli, F., Brustia, L., & Politi, P. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(99)00054-9 · Cited by 168
A review of the literature on the economics of noncompliance. Room for methodological improvement
Cleemput, I., Kesteloot, K., & Geest, S. D. (2002) · Health Policy · doi:10.1016/s0168-8510(01)00178-6 · Cited by 129
Markers of Bone Turnover for Monitoring Treatment of Osteoporosis with Antiresorptive Drugs
Delmas, P. D. (2000) · Osteoporosis International · doi:10.1007/s001980070007 · Cited by 120
Urquhart, J., & de Klerk, E. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980215)17:3<251::aid-sim762>3.0.co;2-a · Cited by 116
Comparing compliance patterns between randomized treatments
Vrijens, B., & Goetghebeur, E. (1997) · Controlled Clinical Trials · doi:10.1016/s0197-2456(96)00235-8 · Cited by 114
Simmons, M. S., Nides, M. A., Rand, C. S., Wise, R. A., & Tashkin, D. P. (2000) · CHEST Journal · doi:10.1378/chest.118.2.290 · Cited by 113
Ettinger, B. B. (1998) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.1998.4.5.488 · Cited by 97
Jamal, S. A., Ridout, R., Chase, C., Fielding, L. J., Rubin, L. A., & HAWKER, G. A. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.12.2143 · Cited by 93
MEDICATION COMPLIANCE AS A FEATURE IN DRUG DEVELOPMENT
Kastrissios, H., & Blaschke, T. F. (1997) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.451 · Cited by 87
Faulkner, D. L., Young, C., Hutchins, D. S., & McCollam, J. S. (1998) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-199805040-00008 · Cited by 86
Initiation of Osteoporosis Treatment after Bone Mineral Density Testing
Pressman, A. R., Forsyth, B. R., Ettinger, B. B., & Tosteson, A. N. A. (2001) · Osteoporosis International · doi:10.1007/s001980170099 · Cited by 74
Randomized Trial of Osteoporosis Screening
Torgerson, D. J. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.18.2121 · Cited by 55
Ethics in Adherence Promotion and Monitoring
Rand, C. S., & Sevick, M. A. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00085-4 · Cited by 53
Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen
Kayser, J., Ettinger, B. B., & Pressman, A. R. (2001) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200109000-00006 · Cited by 46
Ruminations on the Intent-to-Treat Principle
Begg, C. B. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00050-7 · Cited by 42
Monitoring for Adherence: Ethical Considerations
Levine, R. J. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.2.8306018 · Cited by 40
Cited by
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945
Compston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449
Interventions for enhancing medication adherence
Haynes, R. B., Ackloo, E., Sahota, N., McDonald, H. P., & Yao, X. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub3 · Cited by 1,244
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Self-citationCamacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Metadata
- Authors
- Clowes, J. A., Peel, N. F. A., & Eastell, R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-03
- Volume
- 89
- Issue
- 3
- Pages
- 1117-1123
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2171905885
- Cited by
- 334
- References
- 35
- FWCI
- 22.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.